Efficacy of taurine-enhanced enteral nutrition in improving the outcomes of critically ill patients: A systematic review and meta-analysis

• Published in: Clinical nutrition ESPEN 2024-06, Vol.61, p.203-211
• Main Authors: Zhang, Chi, Sun, Ming-wei, Yang, Guang-yu, Wang, Yu, Lu, Charles Damien, Jiang, Hua
• Format: Article
• Language: English
• Subjects: Critical Illness - therapy; Critically; Enteral nutrition; Enteral Nutrition - methods; Humans; Intensive Care Units; Length of Stay; Meta-analysis; Randomized Controlled Trials as Topic; Systematic review; Taurine; Taurine - therapeutic use; Treatment Outcome
• ISSN: 2405-4577; 2405-4577
• DOI: 10.1016/j.clnesp.2024.03.012

Taurine is considered an immunomodulatory agent. From current reports on clinical studies, we conducted a systematic review and meta-analysis to investigate the effects of taurine-enhanced enteral nutrition (EN) on the outcomes of critically ill patients to resolve conflicting evidence in literature. Literature from PubMed, EMBASE, Web of Science, Cochrane Library, CNKI, SINOMED, and WanFang databases were retrieved, and randomized controlled trials (RCTs) were identified. The time range spanned from January 1, 2000, to January 31, 2024. The Cochrane Collaboration Tool was used to evaluate the risk of bias. We used the GRADE approach to rate the quality of evidence and the I2 test to assess the statistical heterogeneity of the results. Risk ratio (RR), mean difference (MD), and 95% confidence interval (95% CI) were used to analyze measurement data. Four trials involving 236 patients were finally included. The meta-analysis results indicated that taurine-enhanced EN did not reduce mortality (RR = 0.70, p = 0.45, 95% CI [0.28, 1.80], two trials, 176 participants, low quality). There was also no significant difference in length of stay in the intensive care unit (ICU) between the taurine-enhanced EN and control groups. Taurine-enhanced EN may reduce pro-inflammatory factor interleukin-6 (IL-6) levels in critically ill patients（the result about IL-6 cannot be pooled）. However, taurine-enhanced EN had no significant impact on high-sensitivity-C-reactive protein levels (MD = −0.41, p = 0.40, 95% CI [-1.35, 0.54], two trials, 60 participants, low quality). Taurine-enhanced EN may reduce IL-6 levels and is not associated with improved clinical outcomes in critically ill patients, which may have potential immunoregulatory effects in critically ill patients. Given that published studies have small samples, the above conclusions need to be verified by more rigorously designed large-sample clinical trials.